中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病体外模型的研究进展

卢晓臣 韩红梅

引用本文:
Citation:

非酒精性脂肪性肝病体外模型的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.01.035
基金项目: 

国家自然科学基金 (81860110)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:卢晓臣负责分析资料,撰写论文,修改论文;韩红梅负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    韩红梅,hanhm79@126.com

Research advances in in vitro models for nonalcoholic fatty liver disease

Research funding: 

National Natural Science Foundation of China (81860110)

  • 摘要: 非酒精性脂肪性肝病发病率逐年上升,其治疗手段有限,对其发病机制的研究是当前热点。为了更好地阐明其发病机制,迫切需要开发先进、安全、有效的体外模型或体内模型,以了解并制订针对该疾病的治疗策略。本文回顾了目前常用于非酒精性脂肪性肝病临床前研究的体外模型,并讨论了其各自的优缺点,为研究非酒精性脂肪性肝病发病机制及治疗提供理论依据。

     

  • [1] OVERI D, CARPINO G, FRANCHITTO A, et al. Hepatocyte injury and hepatic stem cell niche in the progression of non-alcoholic steatohepatitis[J]. Cells, 2020, 9(3): 590. DOI: 10.3390/cells9030590.
    [2] LIU W, BAKER RD, BHATIA T, et al. Pathogenesis of nonalcoholic steatohepatitis[J]. Cell Mol Life Sci, 2016, 73(10): 1969-1987. DOI: 10.1053/j.gastro.2016.02.066.
    [3] ULLAH R, RAUF N, NABI G, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: Recent updates[J]. Int J Biol Sci, 2019, 15(2): 265-276. DOI: 10.7150/ijbs.30121.
    [4] IPSEN DH, TVEDEN-NYBORG P. Extracellular vesicles as drivers of non-alcoholic fatty liver disease: Small particles with big impact[J]. Biomedicines, 2021, 9(1): 93. DOI: 10.3390/biomedicines 9010093.
    [5] PAN X, QUEIROZ J, HUSSAIN MM. Nonalcoholic fatty liver disease in CLOCK mutant mice[J]. J Clin Invest, 2020, 130(8): 4282-4300. DOI: 10.1172/JCI132765.
    [6] KIM WR, LAKE JR, SMITH JM, et al. OPTN/SRTR 2016 annual data report: Liver[J]. Am J Transplant, 2018, 18(Suppl 1): 172-253. DOI: 10.1111/ajt.14559.
    [7] TILG H, ADOLPH TE, MOSCHEN AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade[J]. Hepatology, 2021, 73(2): 833-842. DOI: 10.1002/hep.31518.
    [8] WILLEBRORDS J, PEREIRA IV, MAES M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59: 106-125. DOI: 10.1016/j.plipres.2015.05.002.
    [9] HUANG F, ZHAO S, YU F, et al. Protective effects and mechanism of meretrix meretrix oligopeptides against nonalcoholic fatty liver disease[J]. Mar Drugs, 2017, 15(2): 31. DOI: 10.3390/md15020031.
    [10] ZEILINGER K, FREYER N, DAMM G, et al. Cell sources for invitro human liver cell culture models[J]. Exp Biol Med (Maywood), 2016, 241(15): 1684-1698. DOI: 10.1177/1535370216657448.
    [11] SORET PA, MAGUSTO J, HOUSSET C, et al. In vitro and in vivo models of non-alcoholic fatty liver disease: A critical appraisal[J]. J Clin Med, 2020, 10(1): 36. DOI: 10.3390/jcm10010036.
    [12] HE WX, YANG JY, XU YJ, et al. Establishment and evaluation of a fructose-induced hepatic steatosis cell model[J]. Chin Hepatol, 2019, 24(6): 638-642. DOI: 10.3969/j.issn.1008- 1704.2019.06.018.

    贺雯茜, 杨金玉, 徐艳娇, 等. 果糖诱导肝脂肪变性细胞模型建立及评价[J]. 肝脏, 2019, 24(6): 638-642. DOI: 10.3969/j.issn.1008-1704.2019.06.018.
    [13] JU L, SUN Y, XUE H, et al. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis[J]. Sci Rep, 2020, 10(1): 3201. DOI: 10.1038/s41598-020-60138-8.
    [14] ZHOU L, TANG J, YANG X, et al. Five constituents in psoralea corylifolia L. Attenuate palmitic acid-induced hepatocyte injury via inhibiting the protein kinase c-α/nicotinamide-adenine dinu cleotide phosphate oxidase pathway[J]. Front Pharmacol, 2020, 10: 1589. DOI: 10.3389/fphar.201 9.01589.
    [15] WILLEBRORDS J, PEREIRA IV, MAES M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59: 106-125. DOI: 10.1016/j.plipres.2015.05.002.
    [16] LUO Y, HE XP, LI X, et al. Establishment and comparative analysis of several kinds of cell fatty degeneration model[J]. Chin Arch Tradit Chin Med, 2017, 35(8): 2074-2077. DOI: 10.13193/j.issn.1673-7717.2017.08.040.

    罗燕, 和兴萍, 李雪, 等. 几种细胞脂肪变性模型的建立与比较分析[J]. 中华中医药学刊, 2017, 35(8): 2074-2077. DOI: 10.13193/j.issn.1673-7717.2017.08.040.
    [17] ANINAT C, PITON A, GLAISE D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells[J]. Drug Metab Dispos, 2006, 34(1): 75-83. DOI: 10.1124/dmd.105.006759.
    [18] HU C, LI L. In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration[J]. Protein Cell, 2015, 6(8): 562-574. DOI: 10.1007/s13238-015-0180-2.
    [19] ROBINTON DA, DALEY GQ. The promise of induced pluripotent stem cells in research and therapy[J]. Nature, 2012, 481(7381): 295-305. DOI: 10.1038/nature10761.
    [20] DEEPAK HB, SHREEKRISHNA N, SAMEERMAHMOOD Z, et al. An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells[J]. J Biol Methods, 2020, 7(3): e135. DOI: 10.14440/jbm.2020.330.
    [21] WONG VW, ADAMS LA, de LÉDINGHEN V, et al. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(8): 461-478. DOI: 10.1038/s41575-018-0014-9.
    [22] LYALL MJ, CARTIER J, THOMSON JP, et al. Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells[J]. Philos Trans R Soc Lond B Biol Sci, 2018, 373(1750): 20170362. DOI: 10.1098/rstb.2017.0362.
    [23] MAZZOLENI G, DI LORENZO D, STEIMBERG N. Modelling tissues in 3D: The next future of pha rmaco-toxicology and food research?[J]. Genes Nutr, 2009, 4: 13-22. DOI: 10.1007/s12263-008-0107-0.
    [24] GREEN CJ, PRAMFALK C, MORTEN KJ, et al. From whole body to cellular models of hepatic triglyceride metabolism: Man has got to know his limitations[J]. Am J Physiol Endocrinol Metab, 2015, 308(1): E1-E20. DOI: 10.1152/ajpendo.00192.2014.
    [25] KRAUSE P, SAGHATOLISLAM F, KOENIG S, et al. Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells[J]. In Vitro Cell Dev Biol Anim, 2009, 45: 205-212. DOI: 10.1016/j.stem.2018.05.027.
    [26] BARBERO-BECERRA VJ, GIRAUDI PJ, CHÁVEZ-TAPIA NC, et al. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH[J]. Toxicol In Vitro, 2015, 29(7): 1753-1758. DOI: 10.1016/j.tiv.2015.07.010.
    [27] ANFUSO B, GIRAUDI PJ, TIRIBELLI C, et al. Silybin modulates collagen turnover in an in vitro model of NASH[J]. Molecules, 2019, 24(7): 280. DOI: 10.3390/molecules24071280.
    [28] JAIN MR, GIRI SR, BHOI B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models[J]. Liver Int, 2018, 38(6): 1084-1094. DOI: 10.1111/liv.13634.
    [29] BALE SS, GOLBERG I, JINDAL R, et al. Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells[J]. Tissue Eng Part C Methods, 2015, 21(4): 413-422. DOI: 10.1089/ten.TEC.2014.0152.
    [30] KOZYRA M, JOHANSSON I, NORDLING Å, et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance[J]. Sci Rep, 2018, 8(1): 14297. DOI: 10.1038/s41598-018-32722-6.
    [31] MUKHERJEE S, ZHELNIN L, SANFIZ A, et al. Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype[J]. Am J Transl Res, 2019, 11(3): 1531-1540. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456529/
    [32] PINGITORE P, SASIDHARAN K, EKSTRAND M, et al. Human multilineage 3D spheroids as a model of liver steatosis and fibrosis[J]. Int J Mol Sci, 2019, 20(7): 1629. DOI: 10.3390/ijms20071629.
    [33] HURRELL T, KASTRINOU-LAMPOU V, FARDELLAS A, et al. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis[J]. Cells, 2020, 9(4): 964. DOI: 10.3390/cells 9040964.
    [34] KIM J, KOO BK, KNOBLICH JA. Human organoids: Model systems for human biology and medicine[J]. Nat Rev Mol Cell Biol, 2020, 21(10): 571-584. DOI: 10.1038/s41580-020-0259-3.
    [35] OUCHI R, TOGO S, KIMURA M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids[J]. Cell Metab, 2019, 30: 374-384. e6. DOI: 10.1016/j.cmet.2019.05. 007.
    [36] KRUITWAGEN HS, OOSTERHOFF LA, VERNOOIJ I, et al. Long-term adult feline liver organoid cultures for disease modeling of hepatic steatosis[J]. Stem Cell Reports, 2017, 8(4): 822-830. DOI: 10.1016/j.stemcr.2017.02.015.
    [37] HAAKER MW, KRUITWAGEN HS, VAANDRAGER AB, et al. Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system[J]. J Vet Intern Med, 2020, 34: 132-138. DOI: 10.1016/j.stemcr.2017.02.015.
    [38] WANG Y, WANG H, DENG P, et al. Modeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system[J]. ACS Biomater Sci Eng, 2020, 6(10): 5734-5743. DOI: 10.1021/acsbiomaterials.0c00682.
    [39] WANG L, QIU YL, WANG JS. Advances in research and application of liver organoids[J]. J Clin Hepatol, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.

    王利, 丘倚灵, 王建设. 肝类器官研究及应用进展[J]. 临床肝胆病杂志, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.
    [40] GORI M, SIMONELLI MC, GIANNITELLI SM, et al. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device[J]. PLoS One, 2016, 11(7): e0159729. DOI: 10.1371/journal.pone.0159729.
    [41] LEE SY, SUNG JH. Gut-liver on a chip toward an in vitro model of hepatic steatosis[J]. Biotechnol Bioeng, 2018, 115(11): 2817-2827. DOI: 10.1002/bit.26793.
    [42] FREAG MS, NAMGUNG B, GHERARDI E, et al. Human nonalcoholic steatohepatitis on a chip[J]. Hepatol Commun, 2020, 5(2): 217-233. DOI: 10.1002/adbi.201900104.
    [43] PALMA E, DOORNEBAL EJ, CHOKSHI S. Precision-cut liver slices: A versatile tool to advance liver research[J]. Hepatol Int, 2019, 13(1): 51-57. DOI: 10.1007/s12072-018-9913-7.
    [44] PRINS GH, LUANGMONKONG T, OOSTERHUIS D, et al. A pathophysiological model of non-alcoholic fatty liver disease using precision-cut liver slices[J]. Nutrients, 2019, 11(3): 507. DOI: 10.3390/nu11030507.
  • 加载中
计量
  • 文章访问数:  819
  • HTML全文浏览量:  246
  • PDF下载量:  157
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-19
  • 录用日期:  2021-06-03
  • 出版日期:  2022-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回